Actionable news
All posts from Actionable news

Hemispherx Biopharma and myTomorrows Collaborate to Make Natural Alpha Interferon Available to Patients that Fail or Become Intolerant to Treatment with Recombinant Interferon in Latin America

AMSTERDAM, November 9, 2015 /PRNewswire/ --

myTomorrows (Amsterdam, the Netherlands) announced today that it has recently signed a contract to collaborate with Hemispherx Biopharma, Inc. (Philadelphia, USA; NYSE MKT: HEB) to provide access to its natural alpha interferon for patients that have become intolerant to treatment with recombinant interferon or where such treatment fails.

Through myTomorrows' Internet-based platform, the product is now made available to patients and doctors in Brazil, Columbia and Chile, through an Early Access Program.

In January 2012, ANMAT (the agency responsible for the national regulation of drugs, foods and medical technology in Argentina) approved the product for treatment of hepatitis C, multiple sclerosis and cancers in patients whose treatment with recombinant alpha interferon fails or who become intolerant to treatment with recombinant alpha interferon as a result of the appearance of neutralizing antibodies. The US FDA and ANMAT also approved the product for the treatment of refractory and recurring external condylomata acuminate.

"We are pleased to include natural alpha interferon on our platform and make...